Visit COVID-19 resources

[Skip to Content]

Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ – (Eye 29, 1630 (December 2015))

Dec 10
2015

Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ Eye 29, 1630 (December 2015). doi:10.1038/eye.2015.190 Author: V P Dave

  • 10 December 2015

Annual acknowledgement of manuscript reviewers – (Eye 29, 1517 (December 2015))

Dec 10
2015

Annual acknowledgement of manuscript reviewers Eye 29, 1517 (December 2015). doi:10.1038/eye.2015.229 Author:

  • 10 December 2015

RCOphth concerned at the continued restriction of second eye cataract surgery by CCGs

Dec 10
2015

The Royal College of Ophthalmologists is concerned to hear that there continues to be a restriction of second eye cataract surgery by some CCGs. The RCOphth stresses that the decision to perform second eye cataract surgery should be based entirely on clinical need. A report by the Scottish Health Technologies Group (Healthcare Improvement Scotland) identified evidence

  • 10 December 2015

Ranibizumab for the treatment of wet AMD: a summary of real-world studies – (Eye Journal AOP)

Dec 04
2015

Ranibizumab for the treatment of wet AMD: a summary of real-world studies Eye advance online publication, December 4 2015. doi:10.1038/eye.2015.217 Author: V Chong

  • 4 December 2015

How safe is the light during ophthalmic diagnosis and surgery – (Eye Journal AOP)

Dec 04
2015

How safe is the light during ophthalmic diagnosis and surgery Eye advance online publication, December 4 2015. doi:10.1038/eye.2015.247 Author: M Wolffe

  • 4 December 2015